Biopharma and Pharma - Pharma Rep Focus

What Chevron’s overturn means for biopharma

Fierce Pharma

AUGUST 23, 2024

For the last 40 years, when federal legislation was ambiguous or left an administrative ga | This week on "The Top Line," we look at the potential effects of the Chevron overturn on the biopharma industry.

Biopharma

Collaborative partnerships key to clearing the path for new biopharma products

Fierce Pharma

APRIL 25, 2024

Where innovation meets obstacles and the cost of drug development skyrockets, the key to unlocking success of groundbreaking products in the biopharma industry will rely heavily on strategic | Collaborative partnerships key to clearing the path for new biopharma products

Biopharma

WuXi Biologics plays defense after US bill brands certain Chinese biopharmas as security threats

Fierce Pharma

JANUARY 29, 2024

New legislation aimed at blocking a group of Chinese biopharma firms from tapping into U.S. New legislation aimed at blocking a group of Chinese biopharma firms from tapping into U.S. federal funding has sent shares tumbling in recent days. | federal funding has sent shares tumbling in recent days.

Biopharma

Capturing COVID: Biopharma through the lens during the pandemic

Fierce Pharma

NOVEMBER 1, 2023

A few months ago, Fierce Pharma asked employees working in the biopharma industry to use photographs to tell their stories during the pandemic. After wreaking havoc on a pandemic level for more than three years, COVID-19 has entered its first endemic season. | Now, we’re showcasing those precious memories here.

Biopharma

Biopharma Pharma

Fierce Pharma Asia—Roche's $850M-plus deal with Regor; Legend's busy week; WuXi firms' asset sale?

Fierce Pharma

OCTOBER 3, 2024

On the same day as Roche's Pharma Day in London, the biopharma giant revealed a high-dollar deal with Chinese-American biotech Regor for the latter's CDK inhibitors. |

Pharma

Pharma Biopharma Sales

For biopharma M&A, the best returns come from small deals: analysts

Fierce Pharma

APRIL 7, 2024

Last year closed with a flurry of big-money biopharma deals. Of the industry’s top 10 acquisitions, six came in the fourth quarter. Market research by McKinsey found that smaller, strategic M&A deals provide greater shareholder returns than multibillion-dollar acquisitions.

Biopharma

Biopharma Marketing

Biopharma staffers exhausted and susceptible to burnout, report says

Fierce Pharma

MAY 24, 2023

Biopharma staffers exhausted and susceptible to burnout, report says kdunleavy Wed, 05/24/2023 - 16:52

Biopharma

SCOTUS overturn of Chevron doctrine opens a Pandora's box for biopharma industry, expert says

Fierce Pharma

AUGUST 27, 2024

An expert recently discussed the ramifications of the ruling during a Fierce Pharma podcast interview. . | In June, when the Supreme Court voted 6-3 to overturn the Chevron doctrine, it brought significant impact for the healthcare industry and federal regulators like the FDA and the Centers for Medicare & Medicaid Services.

Biopharma

Biopharma FDA Pharma Healthcare

Embracing Personalization in Biopharma Patient Support Programs

Fierce Pharma

APRIL 18, 2023

Embracing Personalization in Biopharma Patient Support Programs mteefey Tue, 04/18/2023 - 14:48

Biopharma

Biopharma Patients

In Big Pharma's growth rankings, Lilly took top spot from Novo Nordisk in Q1

Fierce Pharma

MAY 16, 2024

The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year. | The momentum the biopharma industry showed in the fourth quarter of 2023 has continued into this year.

Biopharma

Biopharma Pharma

Sustainability is increasingly important in pharma, but several hurdles are slowing the effort: survey

Fierce Pharma

AUGUST 21, 2024

A survey of 800 biopharma executives shows that sustainability is an increasingly important priority but that companies are struggling to achieve it.

Biopharma

Biopharma Pharma

A tsunami of regulations will require biopharma to look to the high ground of knowledgeable partners

Fierce Pharma

MAY 29, 2024

Already weathering the complex biopharma landscape in the U.S. | A tsunami of regulations will require biopharma to look to the high ground of knowledgeable partners

Biopharma

Patent cliffs, divestitures and maturing biotechs all point to more pharma M&A: analysts

Fierce Pharma

SEPTEMBER 7, 2023

Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. Biopharma M&A is on an uptick compared to the post-pandemic doldrums of the last two years. Analysts anticipate that the trend will continue in 2023 and into 2024 as companies attempt to beef up their portfolios.

Biopharma

Biopharma Pharma

With FTC eyeing biopharma M&A deals, Pfizer refiles paperwork for $43B buyout of Seagen

Fierce Pharma

JUNE 14, 2023

billion buyout of Horizon Therapeutics has raised concerns that the United States’ antitrust watchdog is tightening the screws on major M&A moves in the biopharma industry. An FTC lawsuit aimed at blocking Amgen’s $27.8 billion buyout o | An FTC lawsuit aimed at blocking Amgen’s $27.8

Biopharma

Biopharma industry lobbies for tax breaks related to US-based manufacturing

Fierce Pharma

MARCH 21, 2023

Biopharma industry lobbies for tax breaks related to US-based manufacturing kdunleavy Tue, 03/21/2023 - 11:14

Biopharma

Biopharma Manufacturing

In biopharma, employees at Novartis, GSK, AZ and Genentech are most satisfied with their compensation: analysis

Fierce Pharma

JANUARY 16, 2024

A USA Today review of millions of Glassdoor ratings found that employees in the biopharma industry are the most satisfied with their pay compared with other fields. 2023 was riddled with labor strikes across industries as workers lobbied for higher pay amid economic headwinds that shook up the global economy. |

Biopharma

FTC seeks to block Amgen's $28B Horizon buy in 'broadly negative' move for biopharma M&A: report

Fierce Pharma

MAY 16, 2023

FTC seeks to block Amgen's $28B Horizon buy in 'broadly negative' move for biopharma M&A: report aliu Tue, 05/16/2023 - 09:41

Biopharma

In atypical Big Pharma-VC pact, Gilead secures $210M from Abingworth to fund Trodelvy trials

Fierce Pharma

FEBRUARY 29, 2024

Venture capital firms pitching in on drug development isn’t exactly a new way of doing business for the biopharma industry. Venture capital firms pitching in on drug development isn’t exactly a new way of doing business for the biopharma industry.

Biopharma

Biopharma Pharma

Pfizer, Moderna among many biopharma giants to post Q1 sales declines, as Novo Nordisk led growth charge

Fierce Pharma

MAY 22, 2023

Pfizer, Moderna among many biopharma giants to post Q1 sales declines, as Novo Nordisk led growth charge kdunleavy Mon, 05/22/2023 - 13:04

Biopharma

Biopharma Sales

FTC, amid biopharma M&A drive, says it will take action against 'sham' patents

Fierce Pharma

SEPTEMBER 14, 2023

Amid the Federal Trade Commission's (FTC's) campaign to bolster scrutiny around large biopharma M&A deals, the agency is now taking a closer look at patent gamesmanship. |

Biopharma

Biopharma Pharmaceutical

Coming and going paid off for biopharma CEOs in 2022

Fierce Pharma

JUNE 26, 2023

But there was no evidence of the slide in biopharma where pay increases were plentiful. There was a decline in CEO compensation overall in 2022.

Biopharma

How can biopharma strengthen its resilience?

European Pharmaceutical Review

JUNE 7, 2023

The global biopharma industry’s resilience has decreased since 2021, a report by Cytiva has found. Using feedback from 1250 pharma and biopharma executives in 22 countries, the research sought to find out how has the biopharma industry has evolved over the past two years and what areas the industry should seek to improve.

Biopharma

Biopharma Government Manufacturing Pharma

Pharma firepower, M&A surge last year bode well for dealmaking prospects in 2024: EY

Fierce Pharma

JANUARY 8, 2024

Biopharma companies looking to maximize the visibility of their M&A activity often reveal deals during the J.P. In it’s annual Firepower report, EY says the biopharma industry enters 2024 with the capability and motivation to increase M&A activity. Morgan Healthcare Conference. |

Prospecting

Prospecting Biopharma Pharma Healthcare

Number of ongoing US drug shortages reaches new high, pharmacist group says

Fierce Pharma

APRIL 11, 2024

As lawmakers, biopharma companies and others try to stabilize vulnerable pharma supply chains, drug shortages have become about as bad as they’ve ever been in the U.S. | The American Society of Health-System Pharmacists has released new data showing there were 323 drugs in shortage in the U.S.

Biopharma

Biopharma Pharma

The Direct-to-Patient Platform: Transforming the Patient Journey for Better Outcomes

Fierce Pharma

OCTOBER 3, 2024

Matthew Walsh, General Manager of Biopharma at ixlayer - the leading cloud-based platform powering an end-to-end, direct-to-patient healthcare solution - sat down with Fierce at Digital Phar | Matthew Walsh, General Manager of Biopharma at Ixlayer – a cloud-based platform specialist empowering operational efficiency, patient access, and improved outcomes (..)

Patients

Patients Biopharma Management Pharma

2023 forecast: An 'inflection point' for biopharma, fueled by a flood of AI and machine learning products

Fierce Pharma

DECEMBER 20, 2022

2023 forecast: An 'inflection point' for biopharma, fueled by a flood of AI and machine learning products. Tue, 12/20/2022 - 13:39.

Biopharma

Let's make a deal: Conditions are right for biopharma M&A to break out, analysts say

Fierce Pharma

MAY 9, 2023

Let's make a deal: Conditions are right for biopharma M&A to break out, analysts say kdunleavy Tue, 05/09/2023 - 10:18

Biopharma

Despite fears over RFK Jr. pick, industry should focus more on FDA job: analyst

Fierce Pharma

NOVEMBER 18, 2024

may not rock the boat as much as feared for the biopharma industry. Robert F. | In a contrarian take offered by BMO Capital Markets' Evan Seigerman, the analyst said Robert F. Kennedy Jr.

Biopharma

Biopharma FDA Marketing

'The Top Line': The 20 most influential people in biopharma, plus this week's headlines

Fierce Pharma

MAY 25, 2023

The Top Line': The 20 most influential people in biopharma, plus this week's headlines tcarey Thu, 05/25/2023 - 14:21

Biopharma

Tamiflu generics in short supply in latest chapter of biopharma's shortage saga

Fierce Pharma

DECEMBER 21, 2022

Tamiflu generics in short supply in latest chapter of biopharma's shortage saga. fkansteiner. Wed, 12/21/2022 - 08:40.

Biopharma

Obesity, diabetes drugs push Novo Nordisk and Eli Lilly to top of pharma's growth pack in Q2

Fierce Pharma

AUGUST 15, 2023

As the coronavirus surged and subsided, several biopharma companies experienced exaggerated revenue spikes and troughs. Thanks to sales of their metabolism drugs, Novo Nordisk and Eli Lilly posted the biopharma industry’s largest revenue gains in the second quarter—by far.

Biopharma

Biopharma Sales Pharma

Alnylam, Intra-Cellular among analyst's top picks for M&A as biopharma dealmaking heats up

Fierce Pharma

APRIL 19, 2023

Alnylam, Intra-Cellular among analyst's top picks for M&A as biopharma dealmaking heats up aliu Wed, 04/19/2023 - 14:39

Biopharma

Mission: Possible: Big Pharmas back star-fronted lung cancer awareness push

Fierce Pharma

SEPTEMBER 25, 2023

A who’s who of biopharma companies have backed a push to rai | A who’s who of biopharma companies have backed a push to raise awareness about lung cancer among Hispanic and Latino Americans, funding a project that has enlisted a Mission: Impossible star to educate the community about risk factors, early warning signs and screening.

Biopharma

Biopharma Education Pharma

Fierce Pharma Asia—Enhertu's encore; Akeso's showstopper; GenScript and Legend's US scrutiny

Fierce Pharma

JUNE 6, 2024

More Chinese biopharma players are coming under scrutiny from U.S. . | AstraZeneca and Daiichi Sankyo are looking at moving their antibody-drug conjugate Enhertu into another new breast cancer patient class. Ahead of the American Society of Clinical Oncology annual meeting, a cancer antibody from Akeso and Summit Therapeutics stole the show.

Biopharma

Biopharma Pharma Patients

Pharma's Q3 growth rankings: GLP-1 drugs from Eli Lilly, Novo Nordisk were once again the big story

Fierce Pharma

NOVEMBER 27, 2023

It was the second straight quarter where the overwhelming success of blood sugar regulating treatments were the dominant story in the biopharma industry. Eli Lilly’s fortunes have turned quickly. | Eli Lilly and Novo Nordisk delivered the highest revenue gains, at 38% and 29%, respectively.

Biopharma

Biopharma Pharma

Astellas Pharma CEO Q&a (Part 2): We Have To Have Alternatives for Prescription Medicine Business

MedCity News

MAY 13, 2024

In part 2 of our Q&A, Okamura addresses the need for biopharma companies to leverage digital technologies in disease management. The post Astellas Pharma CEO Q&a (Part 2): We Have To Have Alternatives for Prescription Medicine Business appeared first on MedCity News.

Prescription

Prescription Medicine Pharma Biopharma

Global Pharma and Biotech Summit 2024: Innovation Under Pressure

PharmExec

NOVEMBER 5, 2024

At the Financial Times’ Global Pharma and Biotech Summit 2024, Christophe Weber, president and CEO, Takeda, discusses how trust and collaboration between the biopharma industry and stakeholders can be implemented to support successful healthcare transformation.

Pharma

Pharma Biopharma Healthcare Healthcare

We want your stories: Biopharma's collective memory of COVID—in photographs

Fierce Pharma

MAY 9, 2023

We want your stories: Biopharma's collective memory of COVID—in photographs aliu Tue, 05/09/2023 - 14:56

Biopharma

Innovation key for boosting UK biopharma competitiveness

European Pharmaceutical Review

JULY 7, 2023

New recommendations to boost the competitiveness in UK biopharma and Medtech sectors have been published by Imperial College London. Technological solutions and policy recommendations for government have been identified as a way to help make sectors such as biopharma and Medtech more innovative and increase their value added.

Competition

Competition Biopharma Government Manufacturing

Eli Lilly Jumps Into Radiopharmaceuticals via $1.4B Point Biopharma Acquisition

MedCity News

OCTOBER 3, 2023

Acquiring Point Biopharma gives Eli Lilly a pipeline of radiopharmaceuticals, including one for prostate cancer that could rival Novartis’s Pluvicto. The deal comes ahead of an expected Phase 3 data readout for that Point therapeutic candidate.

Biopharma

Biopharma Pharma

'The Top Line': 2023's biopharma layoffs, plus this week's headlines

Fierce Pharma

MAY 18, 2023

The Top Line': 2023's biopharma layoffs, plus this week's headlines tcarey Thu, 05/18/2023 - 16:13

Biopharma

Cognizant and Merck Discuss Technology’s Role in Pharma Manufacturing

Fierce Pharma

SEPTEMBER 11, 2023

The adoption of technology and data by biopharma is driving a digital transformation in manufacturing, accelerating the process of bringing molecules from benchside to bedside. My name is Gaurav Marya. I am the Strategic Business Unit Head and Global Head of Mergers and Acquisitions for Life Sciences at Cognizant. |

Manufacturing

Manufacturing Biopharma Pharma

Lawmakers urge FDA to investigate clinical trials run in tandem with China's military

Fierce Pharma

AUGUST 20, 2024

As House lawmakers prepare for a September vote on the controversial BIOSECURE Act, the House Select Committee on the CCP is expanding the scope of its scrutiny on China's biopharma ecosystem. |

Biopharma

Biopharma FDA

Biopharma could reap benefits from SVB UK acquisition

European Pharmaceutical Review

MARCH 31, 2023

GlobalData Pharma Intelligence Center Deals Database found: SVB Financial Group and its subsidiaries were involved in more than $1.4 A Danish pharma company developing peptide-based medicines, expects to recover its $23.4 The post Biopharma could reap benefits from SVB UK acquisition appeared first on European Pharmaceutical Review.

Biopharma

Biopharma Pharma Networking Marketing

What Chevron’s overturn means for biopharma

Collaborative partnerships key to clearing the path for new biopharma products

Trending Sources

WuXi Biologics plays defense after US bill brands certain Chinese biopharmas as security threats

Capturing COVID: Biopharma through the lens during the pandemic

Fierce Pharma Asia—Roche's $850M-plus deal with Regor; Legend's busy week; WuXi firms' asset sale?

For biopharma M&A, the best returns come from small deals: analysts

Biopharma staffers exhausted and susceptible to burnout, report says

SCOTUS overturn of Chevron doctrine opens a Pandora's box for biopharma industry, expert says

Embracing Personalization in Biopharma Patient Support Programs

In Big Pharma's growth rankings, Lilly took top spot from Novo Nordisk in Q1

Sustainability is increasingly important in pharma, but several hurdles are slowing the effort: survey

A tsunami of regulations will require biopharma to look to the high ground of knowledgeable partners

Patent cliffs, divestitures and maturing biotechs all point to more pharma M&A: analysts

With FTC eyeing biopharma M&A deals, Pfizer refiles paperwork for $43B buyout of Seagen

Biopharma industry lobbies for tax breaks related to US-based manufacturing

In biopharma, employees at Novartis, GSK, AZ and Genentech are most satisfied with their compensation: analysis

FTC seeks to block Amgen's $28B Horizon buy in 'broadly negative' move for biopharma M&A: report

In atypical Big Pharma-VC pact, Gilead secures $210M from Abingworth to fund Trodelvy trials

Pfizer, Moderna among many biopharma giants to post Q1 sales declines, as Novo Nordisk led growth charge

FTC, amid biopharma M&A drive, says it will take action against 'sham' patents

Coming and going paid off for biopharma CEOs in 2022

How can biopharma strengthen its resilience?

Pharma firepower, M&A surge last year bode well for dealmaking prospects in 2024: EY

Number of ongoing US drug shortages reaches new high, pharmacist group says

The Direct-to-Patient Platform: Transforming the Patient Journey for Better Outcomes

2023 forecast: An 'inflection point' for biopharma, fueled by a flood of AI and machine learning products

Let's make a deal: Conditions are right for biopharma M&A to break out, analysts say

Despite fears over RFK Jr. pick, industry should focus more on FDA job: analyst

'The Top Line': The 20 most influential people in biopharma, plus this week's headlines

Tamiflu generics in short supply in latest chapter of biopharma's shortage saga

Obesity, diabetes drugs push Novo Nordisk and Eli Lilly to top of pharma's growth pack in Q2

Alnylam, Intra-Cellular among analyst's top picks for M&A as biopharma dealmaking heats up

Mission: Possible: Big Pharmas back star-fronted lung cancer awareness push

Fierce Pharma Asia—Enhertu's encore; Akeso's showstopper; GenScript and Legend's US scrutiny

Pharma's Q3 growth rankings: GLP-1 drugs from Eli Lilly, Novo Nordisk were once again the big story

Astellas Pharma CEO Q&a (Part 2): We Have To Have Alternatives for Prescription Medicine Business

Global Pharma and Biotech Summit 2024: Innovation Under Pressure

We want your stories: Biopharma's collective memory of COVID—in photographs

Innovation key for boosting UK biopharma competitiveness

Eli Lilly Jumps Into Radiopharmaceuticals via $1.4B Point Biopharma Acquisition

'The Top Line': 2023's biopharma layoffs, plus this week's headlines

Cognizant and Merck Discuss Technology’s Role in Pharma Manufacturing

Lawmakers urge FDA to investigate clinical trials run in tandem with China's military

Biopharma could reap benefits from SVB UK acquisition

Stay Connected